Stoke Therapeutics (STOK) Competitors $11.35 -0.28 (-2.41%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. MIRM, AMRX, IBRX, XENE, BHC, GMTX, APLS, ARWR, TWST, and VCELShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Stoke Therapeutics (NASDAQ:STOK) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Which has more risk and volatility, STOK or MIRM? Stoke Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Do analysts prefer STOK or MIRM? Stoke Therapeutics presently has a consensus price target of $23.20, indicating a potential upside of 104.41%. Mirum Pharmaceuticals has a consensus price target of $65.50, indicating a potential upside of 28.71%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Stoke Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better valuation & earnings, STOK or MIRM? Mirum Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$190.91M3.25-$88.98M$0.7914.37Mirum Pharmaceuticals$336.89M7.48-$87.94M-$1.61-31.61 Is STOK or MIRM more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Mirum Pharmaceuticals' net margin of -20.39%. Stoke Therapeutics' return on equity of 19.08% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.33% 19.08% 15.72% Mirum Pharmaceuticals -20.39%-33.63%-11.50% Does the media prefer STOK or MIRM? In the previous week, Stoke Therapeutics had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Stoke Therapeutics and 3 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.95 beat Stoke Therapeutics' score of 0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStoke Therapeutics beats Mirum Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$634.96M$2.84B$5.46B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio14.3721.1526.4419.67Price / Sales3.25259.51405.32110.29Price / CashN/A41.2925.8827.49Price / Book2.637.247.945.42Net Income-$88.98M-$55.05M$3.15B$248.34M7 Day Performance-1.39%-1.01%0.63%0.81%1 Month Performance18.11%5.98%4.96%5.01%1 Year Performance-18.17%0.83%32.55%18.10% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.9907 of 5 stars$11.35-2.4%$23.20+104.4%-16.0%$634.96M$190.91M14.37100MIRMMirum Pharmaceuticals3.6177 of 5 stars$50.28-0.1%$65.50+30.3%+48.8%$2.49B$336.89M-31.23140Positive NewsAnalyst UpgradeAMRXAmneal Pharmaceuticals3.0274 of 5 stars$7.91+1.2%$11.60+46.6%+27.4%$2.48B$2.79B-197.708,100IBRXImmunityBio2.0663 of 5 stars$2.76-3.8%$12.25+343.8%-58.2%$2.44B$14.74M-4.76590XENEXenon Pharmaceuticals3.1149 of 5 stars$31.49-1.7%$54.82+74.1%-19.7%$2.42B$9.43M-9.75210BHCBausch Health Cos3.8343 of 5 stars$6.11-1.1%$7.42+21.4%-4.2%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+20.9%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.4958 of 5 stars$17.62-0.4%$40.05+127.3%-54.9%$2.21B$775.84M-9.84770Positive NewsARWRArrowhead Pharmaceuticals3.75 of 5 stars$15.51+1.2%$43.71+181.8%-39.2%$2.14B$3.55M-11.08400TWSTTwist Bioscience4.4194 of 5 stars$35.33+2.0%$50.40+42.7%-25.3%$2.12B$347.68M-10.87990VCELVericel2.8863 of 5 stars$41.80-0.5%$61.14+46.3%-7.3%$2.10B$237.22M1,393.80300Positive News Related Companies and Tools Related Companies MIRM Alternatives AMRX Alternatives IBRX Alternatives XENE Alternatives BHC Alternatives GMTX Alternatives APLS Alternatives ARWR Alternatives TWST Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts